The haemolytic anaemias, congenital and acquired / by J.V. Dacie.

  • Dacie, John V. (John Vivian), Sir.
Date:
1954
Catalogue details

Licence: Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)

Credit: The haemolytic anaemias, congenital and acquired / by J.V. Dacie. Source: Wellcome Collection.

    574/580 (page 524)
    524 Index Sickle-cell anaemia, 139, 140-143 aplastic crises, 143 auto-antibodies in, 156 blood picture, 141-142 cardiac enlargement, 141 clinical features, 140-141 pathogenesis, 154—156 pathology, 142-143 plasma bilirubin, 142 proteins, 142 pregnancy, 157 prognosis, 157 spleen, 143, 155 thromboses, 143, 155 treatment, 156 A.C.T.H., 157 splenectomy, 157 X-ray changes, 141 Sickle-cell disease, 138-157 history, 138 in Greece, 139 in India, 139 inheritance, 139-140 racial characteristics, 139 relation to malarial infection, 139 synonyms, 138 Sickle-cell haemoglobin haemoglobin- C disease, 144^145 Sickle-cell haemoglobin haemoglobin- D disease, 146-148 Sickle-cell thalassemia disease, 143- 144 Sicklemia, 139 Sickle-cell trait, 139-140 Sickling phenomenon, 148-149 biochemical changes, 156 demonstration, 502 in newborn, 149 method for inducing, 149, 502 of reticulocytes, 149, 155 Siderocytes, 19-22 efíect of splenectomy, 20-22, 392 in acetylphenylhydrazine poisoning, 385 in acquired haemolytic anaemia, 170-171 in congenital anaemia of mice, 19 in embryos, 19 in haemolytic disease of the newborn, 21 in hereditary spherocytosis, 21, 79 in liver disease, 364 in Mediterranean anaemia, 124 in S3nidromes allied to Mediterranean anaemia, 130 Siderocytosis, 19-22 Siderosis of the kidney, 6, 181, 419 Siderotic granules, 19-22 in normoblasts, 20-21, 391-392 removal by the spleen, 20-21 Specificity of auto-antibodies, 231-234, 246-249, 488-489 Spherical forms, 9 diSerentiation from spherocytes, 9 stages in development, 9 Spherocytes, 8-13 acid-fragility of, 11 acquired, 12 mechanism of production, 302-303 autohaemolysis, 11—12 effect of glucose on, 11 hereditary (congenital), 10-11, 55-58 life-span, 11 osmometric behaviour, 10 tj^es of, 10 Spherocytosis, 8-13 in acquired haemolytic anaemia, 170, 303 in burns, 404 development in vitro, 301 differentiation from spherical forms, 9 in experimental haemolytic anaemias, 301- 302 in haemoljrtic anaemia with ovarian tumours, 348-349 in hereditary elliptocytosis, 11-12 spherocytosis, 55-58 in myelosclerosis, 334 in relation to haemolysis in vivo, 300-303 in secondary haemolytic anaemias, 329, 334, 336-337, 340 in sulphonamide haemolytic anaemia, 394 relation to osmotic fragility, 9 Spleen, accessory spleens, 74-75 bilirubin content of spleen blood, 83, 207, 305 in acquired haemolytic anaemia, 169, 180 in experimental haemolytic anaemia, 305 in hereditary spherocytosis, 54, 70-71, 82-85 in leukaemia with haemolytic anaemia, 336 in lymphadenoma with haemolytic anaemia, 331, 335 in paroxysmal nocturnal haemoglobinuria, 414, 419 visualization by thorotrast, 75 Splenectomy, in acetylphenylhydrazine poisoning, 385-387 in acquired haemolytic anaemia, 198, 206- 207, 305-306, 314-315, 323 in congenital non-spherocytic haemolytic anaemia, 104, 105-107 in experimental haemolytic anaemia, 305 in haemolytic anaemia with ovarian tumours, 348-349 in hereditary elliptocytic haemolytic anaemia, 101 spherocytosis, 72-80 in leaxi poisoning, 392 in paroxysmal nocturnal haemoglobinuria, 436-437 in secondary haemolytic anaemias, 342-344